Is Veracyte (VCYT) overvalued or fairly valued?

MarketChacha shows Veracyte's valuation in context — a trailing P/E of about 86.8, a forward P/E of about 30.8, a price-to-book of about 3.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Veracyte's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (15.89×) from reported figures — education, not a rating.

What is Veracyte's revenue?

Veracyte reported revenue of $517.1M for FY2025, with net profit of $66.4M, per official filings.

What is the share price of Veracyte (VCYT)?

Veracyte last traded at $58.17 (-2.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Veracyte

VCYT · NYSE · Healthcare · United States

$58.17-2.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:29 PM

Snapshot

TickerVCYT

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees755

HeadquartersSouth San Francisco, United States

Market cap$4.6B

P/E (TTM)86.8

P/B3.5

Volume284.71K

Websitewww.veracyte.com

Filings tracked3

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.5%
Institutions99.5%
Public & other0.0%

464 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.16.51%
FMR, LLC9.73%
Artisan Partners Limited Partnership6.89%
State Street Corporation6.32%
Vanguard Portfolio Management LLC5.57%
Vanguard Capital Management LLC4.43%
ARK Investment Management, LLC3.83%
Dimensional Fund Advisors LP3.61%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of 5.1% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion15.89×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-20.6% → 12.8%

Margin has expanded by about 33.4 points — the business is getting more profitable.

Return on equity5.1%

Latest ROE of 5.1% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $148.8M · EPS 0.44

Est. earnings growth -14.3%

Next fiscal year

Rev $654.9M · EPS 1.89

Est. earnings growth +4.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$22.9252-wk range$60.91

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$4.6B

Day change

-2.3%

P/E (TTM)

86.8

Fwd P/E

30.8

P/B

3.5

Beta

1.93

Revenue (FY2025)

$517.1M

Net margin

12.8%

ROE

5.1%

Revenue CAGR (2y)

+19.7%

EPS (FY2025)

0.82

Net profit (FY2025)

$66.4M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about VCYT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$517.1M	$66.4M	0.82	12.8%	5.1%
FY2024	$445.8M	$24.1M	0.31	5.4%	2.1%
FY2023	$361.1M	$-74.4M	-1.02	-20.6%	-7.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$139.1M	$28.7M	0.35	20.6%
2025Q3	$131.9M	$19.1M	0.24	14.5%
2025Q2	$130.2M	$-980,000	-0.01	-0.8%
2025Q1	$114.5M	$7.0M	0.09	6.2%
2024Q3	$115.9M	$15.2M	0.19	13.1%
2024Q2	$114.4M	$5.7M	0.07	5.0%
2024Q1	$96.8M	$-1.9M	-0.02	-1.9%
2023Q3	$90.1M	$-29.6M	-0.41	-32.9%
2023Q2	$90.3M	$-8.4M	-0.12	-9.3%
2023Q1	$82.4M	$-8.1M	-0.11	-9.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results
SEC6/11/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.